Skip to main content
. 2019 Apr 26;11:3611–3619. doi: 10.2147/CMAR.S199260

Table 1.

Characteristics of studies included in this meta-analysis

Reference Country Patient
number		 Tumor type Testing
time		 Cutoff level Clinical factors Quality
score
Jia et al (2018)9 China 131 TNBC Baseline 250 U/L OS, PFS 11
Petekkaya et al (2017)5 Turkey 77 Metastatic BC Diagnosis 480 U/L OS 11
Chen et al (2016)14 China 253 Nonmetastatic TNBC Pretreatment 165 U/L OS, PFS 10
Liu et al (2015)15 USA 2,425 Nonmetastatic BC Pretreatment 469 U/L OS 9
Petekkaya et al (2014)16 Turkey 652 Nonmetastatic BC Postoperation 480 U/L OS, PFS 10
Bidard et al (2012)17 France 267 Metastatic BC Baseline ULNV PFS 10
Brunetto et al (2010)18 UK 70 Metastatic BC Not reported Normal OS 9
Er et al (2008)19 USA 132 Liver-metastatic BC Pretreatment Normal OS, PFS 9
Pierga et al (2001)20 France 1,430 Metastatic BC Pretreatment 330 U/L OS 8
Ryberg et al (2001)21 Denmark 469 Metastatic BC Pretreatment 450 U/L OS 8
Yamamoto et al (1998)22 Japan 196 Metastatic BC Registration Normal OS 7

Abbreviations: TNBC, triple-negative breast cancer; BC, breast cancer; ULNV, upper limit of normal value; OS, overall survival; PFS, progression-free survival.